Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.
about
Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategiesEmerging treatment options for myelofibrosis: focus on pacritinibRecent advances in understanding myelofibrosis and essential thrombocythemiaOvercoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinibInflammation as a Keystone of Bone Marrow Stroma Alterations in Primary MyelofibrosisMPNs as Inflammatory Diseases: The Evidence, Consequences, and PerspectivesCirculating Cytokine Levels as Markers of Inflammation in Philadelphia Negative Myeloproliferative Neoplasms: Diagnostic and Prognostic InterestGuidelines for the management of myeloproliferative neoplasmsCytokine Regulation of Microenvironmental Cells in Myeloproliferative NeoplasmsThe Hen or the Egg: Inflammatory Aspects of Murine MPN ModelsImpact of Inflammation on Myeloproliferative Neoplasm Symptom DevelopmentPathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic InflammationAllogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitorsAdvances in the management of myelofibrosisExpression of the TEL-Syk fusion protein in hematopoietic stem cells leads to rapidly fatal myelofibrosis in miceMolecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations.Managing Patients With Myelofibrosis in the Era of Janus Kinase InhibitorsHow ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes.IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromesSerious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis.A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.Immunomodulatory agents in myelofibrosis.Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.Emerging drugs for myelofibrosis.Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis.Practical management of patients with myelofibrosis receiving ruxolitinib.Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing.Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation.Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasmsSelective Janus associated kinase 1 inhibition as a therapeutic target in myelofibrosis.Increased plasma nicotinamide phosphoribosyltransferase is associated with a hyperproliferative phenotype and restrains disease progression in MPN-associated myelofibrosis.Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial.The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 MutationAnti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera.Human monocytes have increased IFN-γ-mediated IL-15 production with age alongside altered IFN-γ receptor signaling.Endogenous retrovirus induces leukemia in a xenograft mouse model for primary myelofibrosis.Clinical significance of microcytosis in patients with primary myelofibrosis.Plasma cytokine concentrations indicate that in vivo hormonal regulation of immunity is altered during long-duration spaceflight.mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.Associations between muscle-related cytokines and selected patient outcomes in the ICU
P2860
Q26744113-07560EC7-6D49-4EB1-B869-129CB169013FQ26745939-9E252446-AD65-4C47-8CE2-BF2DC5A427AEQ26748543-358FCCBD-890D-4B21-8654-2DA1F167590BQ26750696-487927D6-5B8F-49F4-9F7F-4A29DAAF62BBQ26774212-BDF3CF34-14DA-4DE7-B660-192187FB573EQ26775996-CEDC4469-6DFB-4520-AD7E-A43EA8463D7EQ26777398-A8A93FAA-E08E-45A5-B294-024A02BB7D1AQ26778326-469D2C56-8F0D-4560-9A1E-E2DF23BA6F99Q26778929-7DEF42BB-1B95-4712-B4D4-AA3FCE5D5C8BQ26778931-4A2CAB01-E624-4D2F-9D31-3D9848DD4C28Q26779947-B03D1821-E2BB-4629-8FF0-5AECC88927B5Q26779960-E0C8CDA9-3369-4CE0-B37D-86644A2E9281Q26863610-FFDE33DB-F009-4908-B8D4-60CF7DE57042Q27008072-2A4BE622-AE6A-4A60-99A7-277B40C692BFQ27303848-4E233AE9-F9D1-44B3-BD1F-B649E8ED7DD2Q27853374-18EFA762-D4D1-4717-BE69-2BCE7135DD9DQ28073296-9AB1129C-3DF4-4D5F-89D9-29C1D9C87006Q30240043-41DF9A38-3D2B-4A2E-A3EA-BFBD33D13638Q33397165-5FD79D3C-F202-418A-AD62-0C1D8C90F4C3Q33397838-3365C798-A708-4037-8FBD-D1215A7FE901Q33399980-90DD8528-A313-44EB-B7AF-96F909C5502AQ33401615-5645115A-521D-4C9D-9596-3ECEB8910E5DQ33403735-D35384B2-F9C7-4952-A163-8D242A097A9AQ33404574-2A3D88D4-06D9-45C5-95F8-ADA7163A56D3Q33406238-2DFA2D50-E5CE-4027-89E6-88B7FAFCAB86Q33410649-F8FC42E6-45A1-4290-B78C-76F1010FAABEQ33411763-FFDBB863-F4E5-44A4-84EF-274F7F1F6939Q33416494-C1034A31-A614-40AD-A07C-41D26679449DQ33417217-87CFB368-0815-486A-8B26-7A30C2E8ED44Q33419762-B5275F56-4C81-448F-89EF-F8239284748AQ33431469-1944FF83-447D-4B6A-AC8C-C84B15CE233CQ33438420-7AE187BB-F316-47CE-B1C9-2310E12855B0Q33443246-41CB2405-499C-42C0-9A1F-5BFBBEB07574Q33443580-C9CBC5A2-8420-429D-B58A-F510D2989CCAQ33601367-30005913-0437-4FCD-B6FF-DDF2A00EA9CFQ33767496-A262FD27-8738-4A13-9297-430D14506C81Q34276194-954B84E2-4844-4D14-ACFE-DB0F98B7AD58Q34294091-F34F0046-404A-490E-9278-2A8EF169A95BQ34575726-DE4FC3B9-CF20-4D14-862D-BE99BECCAFD2Q34587760-379920F2-ABFC-462F-BBF0-580AAE041552
P2860
Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Circulating interleukin (IL)-8 ...... sive cytokine profiling study.
@ast
Circulating interleukin (IL)-8 ...... sive cytokine profiling study.
@en
type
label
Circulating interleukin (IL)-8 ...... sive cytokine profiling study.
@ast
Circulating interleukin (IL)-8 ...... sive cytokine profiling study.
@en
prefLabel
Circulating interleukin (IL)-8 ...... sive cytokine profiling study.
@ast
Circulating interleukin (IL)-8 ...... sive cytokine profiling study.
@en
P2093
P356
P1476
Circulating interleukin (IL)-8 ...... sive cytokine profiling study.
@en
P2093
Animesh Pardanani
Christy Finke
Domenica Caramazza
Rakhee Vaidya
Terra Lasho
P304
P356
10.1200/JCO.2010.32.9490
P407
P577
2011-02-07T00:00:00Z